VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback